NICE "minded" not to recommend MabThera for Vasculitis
NICE, the National Institute for Health and Care Excellence, is so far "minded not" to recommend MabThera (rituximab) from Roche for anti-neutrophil cytoplasmic antibody-associated Vasculitis. NICE has asked Roche for more information for the next appraisal meeting on 28 August.
Some 1,200 patients in England and Wales are diagnosed each year with ANCA-associated Vasculitis. NICE wants to know more about the definition of severe disease and the subgroup of patients who should avoid cyclophosphamide. It also wants to see more data on the longer term benefits of MabThera and a revised economic model better representing the management of severe ANCA-associated vasculitis in the UK.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.